【Healthkoreanews】The sales of Actonel (Sanofi-aventis Korea's osteoporosiere drug) were recorded 24.8 billion won for the first nine months of 2008, followed by Fosamax Plus and Bonviva.
According to the IMS Health data, Fosamax and Fosamax Plus's sales (MSD Korea’s osteoporosiere drugs) were recorded 17.9 and 7.8 billion won respectively in the same period.
The sales of major osteoporosis drugs for the first nine months of this year are as follows :
Drug/ Sales in billion won/ Sales growth
Actonel/ 24.8/ 7.3%
Fosamax Plus/ 17.9/ 34.3%
Bonviva/ 5.0/7 49.1%
Fosamax/ 7.8/ 16.7%
Maxmarvil/ 5.3/- 12.5% <헬스코리아뉴스>